Business Context and Reporting Period
This Form 8-K is a current report filed by Medtronic Limited (f/k/a Medtronic Holdings Limited) on January 9, 2015. The filing relates to corporate governance changes and a private equity placement occurring in early January 2015. The company is in the process of restructuring to become "New Medtronic" (Medtronic plc) following the previously announced acquisition of Covidien plc.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to a specific equity transaction:
- Equity Issuance: On January 12, 2015, the Company allotted 39,993 Euro Deferred Shares.
- Consideration: Aggregate cash consideration of €39,993.00 (€1.00 par value per share).
- Transaction Type: Private placement to sophisticated investors under Section 4(a)(2) of the Securities Act of 1933.
Material Changes
The filing reports the following material changes to the Board of Directors effective January 9, 2015:
- Resignation: Robert ten Hoedt resigned from the Board of Directors. The filing states this was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment: Gerard Kilcommins, an employee of Medtronic, Inc., was appointed as a director by shareholder written resolution.
- Compensation: Mr. Kilcommins will receive no separate compensation for his director services beyond his existing employee compensation.
- Term: Mr. Kilcommins' service is expected to terminate prior to the consummation of the Covidien plc acquisition.
Outlook, Risks, and Unusual Items
Acquisition Status: The filing emphasizes the ongoing acquisition of Covidien plc. A registration statement on Form S-4, including the Joint Proxy Statement/Prospectus, has been declared effective by the SEC.
Investor Action Required: Investors are urged to read the Joint Proxy Statement/Prospectus carefully as it contains important information regarding the transactions and the formation of "New Medtronic."
Regulatory Compliance: The equity issuance was conducted as an unregistered sale in reliance on a specific exemption. The filing includes standard disclaimers that this communication does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Key Facts for Investor Verification
- Verify the terms and timeline of the pending acquisition of Covidien plc in the Joint Proxy Statement/Prospectus (Form S-4).
- Confirm the final composition of the Board of Directors for the post-merger entity ("New Medtronic").
- Review the details of the €39,993 private placement of Euro Deferred Shares to understand the capital structure implications, however minor.
- Check for any subsequent filings regarding the resignation of Robert ten Hoedt or the appointment of Gerard Kilcommins to ensure no undisclosed disagreements or conflicts of interest exist.